Vilitra 10 contains Vardenafil, a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). While it does not directly increase nitric oxide (NO) production, it enhances the effects of nitric oxide already present in the body.
During sexual stimulation, the body releases nitric oxide in the corpus cavernosum of the penis. Nitric oxide activates the enzyme guanylate cyclase, which increases levels of cyclic guanosine monophosphate (cGMP). This leads to relaxation of smooth muscle cells and dilation of blood vessels, allowing increased blood flow and resulting in an erection.
VILITRA 10 MG works by inhibiting the PDE5 enzyme, which normally breaks down cGMP. By blocking PDE5, Vilitra allows cGMP levels to remain elevated longer, thereby amplifying the natural effects of nitric oxide. This promotes prolonged smooth muscle relaxation and improved erectile function.
Although Vardenafil does not synthesize or release NO directly, it is essential in sustaining its action. For optimal results, sexual stimulation is necessary to initiate the nitric oxide release that triggers this process.
In summary, Vilitra 10 indirectly boosts nitric oxide's impact by preserving cGMP, thereby enhancing blood flow and improving erectile response.
Add your comment